NASDAQ · FEMY

Femasys Inc.

$3.71 -$0.08 (-2.11%) 1D After hours

Key Metrics

$11.44M
Market cap
P/E · TTM
$2.38M
Revenue · TTM
−$11.88M
Net income
EPS · TTM $-0.47
Dividend yield
Free cash flow −$18.58M
Beta · 1Y 1.44
EBITDA · TTM −$11.60M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    From its Mar 16 high, the share price fell 76%.

    Peak close $12.37 on Mar 16; trough close $3.01 on Jul 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -76%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 22
    The stock moved +29.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 22
  • Mar 30
    The stock moved -22.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 30

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$11.44M
Enterprise value
Shares outstanding3.0M
52-wk range$0.31 – $14.51
Avg volume · 20D1.3M
Net cash
Book value / share$0.29
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Femasys Inc.
IPO dateJun 18, 2021
Employees54

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S4.81
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -499.8%
Net -500.0%
FCF -781.5%
ROE / ROIC -247.7% · -624.3%

Financial Health

Current ratio3.91
Quick ratio1.98
Debt / equity
Debt / EBITDA
Net cash
Working capital$9.19M

Cash Flow · TTM

Operating CF −$18.07M
Capex −$507.54K
Free cash flow −$18.58M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-13.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings